Abstract
The antidepressant and other behavioral effects of clorgyline, a preferential inhibitor of monoamine oxidase (MAO) type A, were compared with those of pargyline, a preferential inhibitor of MAO type B, in 16 depressed patients. In a subgroup of more severely depressed patients, clorgyline treatment for 4 weeks resulted in significant improvement on both observer-rated and self-rated scales, while minimal changes occurred during pargyline treatment. Similarly, in a crossover study that included 8 patients examined with multiple scales, clorgyline had generally greater antidepressant and antianxiety effects than did pargyline, although pargyline had some activating effects and also tended to produce more side effects. MAO type A inhibition may be more important than MAO type B inhibition for antidepressant efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cattell, R. B., Scheier, J. H.: Handbook for the IPAT anxiety scale questionnaire, 2d ed. Champaign, Ill. Institute for Personality and Ability Testing 1963
Christmas, A. J., Coulson, C. J., Maxwell, D. R., Riddell D.: A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br. J. Pharmacol. 45, 490–503 (1972)
Dahlstrom, W. G., Welsh, G. S.: An MMPI handbook: a guide to use in clinical practice and research, Minneapolis: University of Minnesota Press 1960
Donnelly, C. H., Murphy, D. L.: Substrate and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26, 853–858 (1977)
Dunlop, E.: Antidepressant effects of MAO inhibitors. Ann. N.Y. Acad. Sci. 107, 1107–1116 (1963)
Fuentes, J. A., Neff, N. H.: Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes. Neuropharmacology 14, 819–825 (1975)
Guy, W.: ECDEU assessment manual for psychopharmacology, DHEW publication No. 76-338. Washington, D.C.: U.S. Government Printing Office 1976
Herd, J. A.: A new antidepressant — M and B9302. A pilot study and a double-blind controlled trial. Clin. Trials 6, 219–225 (1969)
Houslay, M. D., Tipton, K. F., Youdim, M. B. H.: Multiple forms of monoamine oxidase, fact and artifact. Life Sci. 19, 467–478 (1976)
Janecke, J., Schiele, B. C., Vestre, N. D. Pargyline and tranylcypromine in the treatment of hospitalized depressed patients. J. New Drugs 3, 309–316 (1963)
Kline, N. S.: Use of pargyline (Eutonyl) in private practice. Ann. N.Y. Acad. Sci. 107, 1090–1106 (1963)
Murphy, D. L.: Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem. Pharmacol. 27, 1889–1893 (1978)
Murphy, D. L.: The behavioral toxicity of monoamine oxidase inhibiting antidepressants. Adv. Pharmacol. Chemother. 14, 71–105 (1977)
Murphy, D. L., Belmaker, R., Wyatt, R. J.: Monoamine oxidase in schizophrenia and other behavioral disorders. J. Psychiatr. Res. 11, 221–247 (1974)
Murphy, D. L., Buchsbaum, M. S.: Neurotransmitter-related enzymes and psychiatric diagnostic entities. In: Current issues in psychiatric diagnosis, R. L. Spitzer and D. F. Klein (eds.), pp. 305–321. New York: Raven 1978
Murphy, D. L., Campbell, I., Costa, J. L.: Current status of the indoleamine hypothesis of the affective disorders. In: Psychopharmacology: a generation of progress, M. A. Lipton, A. DiMascio and K. F. Killam (eds.), pp. 1235–1247, New York: Raven 1978
Murphy, D. L., Lipper, S., Slater, S., Shilling, D.: Selectivity of clorgyline and pargyline as inhibotors of monoamine oxidases A and B in vivo in man. Psychopharmacology 62, 129–132 (1979)
Murphy, D. L., Redmond, D. E.: The catecholamines: possible role in affect, mood, and emotional behavior in man and animals. In: Catechlamines and behavior, A. J. Friedhoff (ed.), pp. 73–117. New York: Plenum 1975
Neff, N. H., Yang, H.-Y. T.: Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 14, 2061–2074 (1974)
Robinson, D. S., Lovenberg, W., Keiser, H., Sjoerdsma, A.: Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol. 17, 109–119 (1968)
Saunders, J. C.: Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline. Ann. N.Y. Acad. Sci. 107, 1081–1089 (1963)
Spitzer, R. L., Endicott, J., Robins, E.: Research diagnostic criteria: rationale and reliability. Arch. Gen. Psychiatry 35, 837–844 (1978)
Squires, R. F.: Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibition and thermal stability: a comparison of eight mammalian species. Adv. Biochem. Pharmacol. 5, 355–370 (1972)
van Kammen, D. P., Murphy, D. L.: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (Berl.) 44, 215–224 (1975)
Wheatley, D.: Comparative trial of a new mono-amine oxidase inhibitor in depression. Br. J. Psychiatry 117, 573–574 (1970)
Zuckerman, M.: The sensation-seeking motive. In: Progress in experimental personality research, B. Maher (ed.), pp. 79–148. New York: Academic 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lipper, S., Murphy, D.L., Slater, S. et al. Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 62, 123–128 (1979). https://doi.org/10.1007/BF00427124
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00427124